CorNeat EverPatch 

The first synthetic and non-degradable tissue substitute for ophthalmic surgeries

About Ophthalmic Reconstructive Surgery

Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused unintentionally during a previous surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible making patching the area with preserved and processed tissue the only treatment option.

Image by Olga Guryanova

CorNeat KPro

CorNeat EverPatch Advantages 


Inert and non-degradable material

Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response

Ease of


Extremely easy to handle and suture


Elastic and durable (cannot be torn by the sutures)


Synthetic and therefore cannot carry or transmit disease 


Reduces operating time and eye bank costs 


Eliminates complexities related to the transportation and storage of biological materials


Readily available, off-the-shelf, device


Translucent when wet

Hardly visible when implanted subconjunctivally

Eye contact9.jpg

CorNeat EverPatch

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. The CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.  


The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the extracellular matrix, stimulating cellular colonization and integration with the surrounding tissue.


Covering irritating implants such as in glaucoma tube shunts or exposed sutures, displacing the need for preserved tissue/collagen

Covering tissue gaps/weaknesses, resulting from either traumatic, disease related or iatrogenic damage

Eye contact5.jpg

Regulatory Path

The first-in-human (FIH) clinical trial for the CorNeat EverPatch took place on December 2020. The surgery was conducted by Dr. Ike Ahmed at the Prism Eye Institute in Toronto, Canada. Clinical trials will take place in France and Kenya, as well. The trials are geared toward obtaining a CE marking during 2021. CorNeat Vision plans to extend the solution to the US market as a second step and work toward FDA approval. The exact FDA path will be coordinated with authorities in the second half of 2020.

The plans above are subject to regulatory approvals and requirements.

For more information:

Product Animation 

Visit us at
4 HaSheizaf St.

Ra'anana, Israel

Join Our Mailing List